Cell Therapeutics, Inc. today announced the European Medicines Agency Pediatric Committee recommended the Company submit an updated Pediatric Investigation Plan for pixantrone following discussions with the Company about the preclinical and clinical pixantrone data, including PIX301, and the desire to explore the potential benefits pixantrone may offer to children with hematologic cancer.
More...